Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jessica Sachs"'
Autor:
Daniel J. DeAngelo, Vinod A. Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L Heaney, Jessica Sachs, Lei Sun, Amanda Pilla, Benjamin Exter, Hina A. Jolin, Tsewang Tashi
Publikováno v:
Blood. 140:1512-1513
Autor:
Cem Akin, Frank Siebenhaar, Michael W. Deininger, Daniel J. DeAngelo, Tracy I. George, Mariana Castells, Matthew Giannetti, Jason Gotlib, Jessica Sachs, Amanda Pilla, Hina A. Jolin, Prithviraj Bose
Publikováno v:
Blood. 140:6838-6839
Autor:
Frank Siebenhaar, Cem Akin, Jennifer Nicoloro SantaBarbara, Jean Paty, Chad Gwaltney, Michelle Watson, Jessica Sachs, Hina Jolin, Casey Judge, Mariana Castells
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB53
Autor:
Frank Siebenhaar, Jason Gotlib, Michael W. Deininger, Daniel J. DeAngelo, Francis Payumo, George Mensing, Hina Jolin, Jessica Sachs, Tracy I. George
Publikováno v:
Blood. 138:3642-3642
Systemic mastocytosis (SM) is characterized by mast cell infiltration of ≥ 1 extracutaneous organs and encompasses a spectrum of diagnoses that can range from a non-advanced to advanced disease (Shomali et al, 2018). There are two nonadvanced varia
Autor:
John A. Robinson, Francis J. Sullivan, Jessica Sachs, Howard Ball, Karyn Bouhana, Shannon L. Winski, LouAnn Cable, Mark Joseph Chicarelli, Anna Guarnieri
Publikováno v:
Blood. 138:4595-4595
The molecular pathogenesis of Systemic Mastocytosis (SM) is driven by mutations in the KIT gene, with 95% of patients having a mutation in exon 17, D816V, leading to constant proliferation of mast cells (Garcia-Montero et al, 2006; Jara-Acevedo et al
Autor:
Hina Jolin, Prithviraj Bose, Michael W. Deininger, Vinod Pullarkat, Jessica Sachs, Jason Gotlib, Daniel J. DeAngelo, Tsewang Tashi, Tracy I. George, Amanda Pilla, Francis Payumo
Publikováno v:
Blood. 138:3636-3636
Systemic mastocytosis (SM) is characterized by excessive accumulation of mast cells in bone marrow and other extracutaneous tissues encompassing a spectrum of variants ranging from non-advanced to advanced disease (Shomali et al, 2018). Advanced syst
Autor:
Ann Ranger, Jonathon B. Cohen, Francis Payumo, Veronika Bachanova, Patricia L. Harris, Luke P. Akard, Jason R. Westin, Ian W. Flinn, Samantha Jaglowski, Jessica Sachs
Publikováno v:
Blood. 134:1587-1587
Background: The Antibody-Coupled T-cell Receptor (ACTR) platform is an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immu
Autor:
Matthew McKinney, Francis Payumo, Ann Ranger, Samantha Jaglowski, Jessica Sachs, Patrick J. Stiff, Iris Isufi, Luke P. Akard, Patricia Harris, Javier Munoz
Publikováno v:
Blood. 134:244-244
Background: The Antibody-Coupled T-cell Receptor (ACTR) platform is an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immu
Autor:
Sam Song, Franco Locatelli, Thomas Klingebiel, Kathleen A. Neville, Gregory Song, Aurora Medina-Sanson, Judith Kinley, Nathalie Aladjidi, Jessica Sachs, Christine Mauz-Koerholz, Anna Llort, Stephen Daw, Ashish Suri, Kristen Hoffman, Stephen Zhang, Judith Landman-Parker, Keith J. August, Lia Gore, Auke Beishuizen, Marta Pillon
Publikováno v:
Lancet Haematology, 5(10), E450-E461. Lancet Publishing Group
Summary Background Despite remarkable progress in the treatment of newly-diagnosed classical Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, treatment of relapsed or refractory disease remains challenging. The aims of this study were
Autor:
Greg Motz, Veronika Bachanova, Patricia L. Harris, Luke P. Akard, Kathleen E. McGinness, Jonathon B. Cohen, Jessica Sachs, Ann Ranger, Ian W. Flinn, Samantha Jaglowski
Publikováno v:
Cancer Immunology Research. 7:A003-A003
Background: Autologous T cells engineered to express a universal ACTR chimeric receptor kill tumors through interactions with tumor-targeting antibodies [Kudo, Cancer Res 2014]. ACTR707 was identified through rigorous preclinical screening of more th